Clinical Trial Update: Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes Glumetinib combined with Fruquintinib being studied for MET amplification or overexpression in third-line unresectable meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Glumetinib

Snippet

Sponsor: Liu Huang | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING